Back to Search
Start Over
The association between drospirenone and hyperkalemia: a comparative-safety study.
- Source :
-
BMC clinical pharmacology [BMC Clin Pharmacol] 2011 Dec 30; Vol. 11, pp. 23. Date of Electronic Publication: 2011 Dec 30. - Publication Year :
- 2011
-
Abstract
- Background: Drospirenone/ethinyl-estradiol is an oral contraceptive (OC) that possesses unique antimineralocorticoid activity. It is conjectured that drospirenone, taken alone or concomitantly with spironolactone, may be associated with an increased risk of hyperkalemia.<br />Methods: A retrospective cohort study was conducted evaluating women between 18-46 years of age in the Lifelinkā¢ Health Plan Claims Database. The study was restricted to new users of OCs between 1997-2009. Cox proportional hazards models were used to estimate the time to first occurrence of hyperkalemia diagnosis. The main analysis compared OCs containing drospirenone with OCs containing levonorgestrel, a second generation OC not known to impact potassium homeostasis. Logistic regression evaluated concomitant prescribing of drospirenone and spironolactone<br />Results: The cohort included 1,148,183 women, averaging 28.8 years of age and 280 days of OC therapy. 2325 cases of hyperkalemia were identified. The adjusted hazard ratio (HR) for hyperkalemia with drospirenone compared to levonorgestrel was 1.10 (95%CI 0.95-1.26). There was an increased risk of hyperkalemia with norethindrone HR 1.15 (95%CI: 1.00-1.33) and norgestimate HR 1.27 (95%CI: 1.11-1.46). Other OCs were unassociated with hyperkalemia. The odds of receiving spironolactone while taking drospirenone were 2.66 (95%CI 2.53-2.80) times higher than the odds of receiving spironolactone and levonorgestrel. Only 6.5% of patients taking drospirenone and spironolactone had a serum potassium assay within 180 days of starting concomitant therapy.<br />Conclusions: A clinically significant signal for hyperkalemia with drospirenone was not demonstrated in the current study. Despite the bolded warning for hyperkalemia with joint drospirenone and spironolactone administration, physicians are actually using them together preferentially, and are not following the recommended potassium monitoring requirements in the package insert.
- Subjects :
- Adult
Androstenes administration & dosage
Cohort Studies
Contraceptives, Oral, Combined adverse effects
Contraceptives, Oral, Combined therapeutic use
Ethinyl Estradiol administration & dosage
Ethinyl Estradiol adverse effects
Female
Follow-Up Studies
Humans
Levonorgestrel therapeutic use
Logistic Models
Proportional Hazards Models
Retrospective Studies
Risk Factors
Spironolactone therapeutic use
Androstenes adverse effects
Hyperkalemia chemically induced
Subjects
Details
- Language :
- English
- ISSN :
- 1472-6904
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- BMC clinical pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 22208934
- Full Text :
- https://doi.org/10.1186/1472-6904-11-23